Chikungunya disease is caused by the chikungunya virus, which is transmitted through the bite of infected mosquitoes. The disease is found in countries across Asia, Africa and the subtropical regions of the Americas. Most people infected with the virus develop fever, rash, and severe pain in multiple joints that typically resolve between one to two weeks, but symptoms may last for months or years. 

This vaccine has been approved through the International Recognition Procedure (IRP). The IRP allows the MHRA to take into account the expertise and decision-making of trusted regulatory partners for the benefit of UK patients.  

The MHRA conducts a targeted assessment of IRP applications and retains the authority to reject applications if the evidence provided is not considered sufficiently robust. 

As with any medicine, the MHRA will keep the safety and effectiveness of this vaccine under close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.  

Notes to editors   

1. The variation to the marketing authorisation was granted on 01 May 2025 to Bavarian Nordic A/S.  

2. More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on the MHRA Products website within 7 days of approval.   

3. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.  All our work is underpinned by robust and fact-based judgments to ensure that the benefits justify any risks.   

4. The MHRA is an executive agency of the Department of Health and Social Care.   

5. For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.